Description | Symbol | Value(s) | References |
---|---|---|---|
Untreated infections | |||
 Mean duration of state (days) |  |  | [17] |
  D (clinical disease) | dD | 5 |  |
  A (asymptomatic) | dA | 195 |  |
  U (submicroscopic) | dU | 84 |  |
 Probability of human-to-mosquito transmission per mosquito bite from individuals in state |  |  | [17] |
  D (clinical disease) | cD | 0.0868596 |  |
  A (asymptomatic) | cA | cD > cA > cU varies by immunity |  |
  U (submicroscopic) | cU | 0.0023444 |  |
 Total infectivity over the infectious period in untreated, initially symptomatic infections | Otot | cDdD + cAdA + cUdU | – |
 Proportion of infections which develop symptoms | φ | 0.00038–0.81 (immunity-dependent) |  |
Treated infections | |||
 Drug efficacy: probability the drug eventually clears parasites | peff | 0.97 | [6] |
 % reduction Otot in total infectivity over the infectious period achieved by treatment with: |  |  | [17] |
  SP | Ored | 79.1% |  |
  ACT |  | 92.7% |  |
  ACT + primaquine |  | 100% |  |
 Mean duration of state |  |  | [17] |
  PDT, PAU, or PS (prophylaxis) | dP | 3, 30, 60 |  |
  T | dT | 5 |  |
 Probability of human-to-mosquito transmission per mosquito bite from individuals in state |  |  | This paper |
  T (will soon receive treatment) | cT | cD |  |
  PDT (prophylaxis) | cPDT | Otot * (1 − Ored/100)/dP |  |
  PAU (prophylaxis) | cPAU | cA * cPDT/cD |  |
 MDA coverage: proportion of individuals receiving MDA | fMDA | 0.8 | – |
 Case management coverage: proportion of cases treated | fT | 0.4–1 | – |